Adaptive Biotechnologies ADPT Deferred revenue, net of current portion
Deferred revenue, net of current portion at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's deferred revenue, net of current portion.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's deferred revenue, net of current portion?
- Adaptive Biotechnologies (ADPT) reported deferred revenue, net of current portion of $807K in Q1 2026.
- How has Adaptive Biotechnologies's deferred revenue, net of current portion changed year-over-year?
- Adaptive Biotechnologies's deferred revenue, net of current portion decreased by 96.7% year-over-year, from $24.81M to $807K.
- What is the long-term trend for Adaptive Biotechnologies's deferred revenue, net of current portion?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's deferred revenue, net of current portion has grown at a -63.9% compound annual growth rate (CAGR), from $163.62M to $1.01M.